News Archive

May 2018

• Press Release May 17, 2018

  Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer

  Results from the Kisqali® MONALEESA clinical trial program, the largest industry- sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will…
• Press Release May 16, 2018

  Novartis kündigt Veränderungen in der Geschäftsleitung an

  Felix R. Ehrat, Group General Counsel, tritt per 1. Juni 2018 zurück Shannon Thyme Klinger zum Group General Counsel ernannt Robert Weltevreden zum Leiter Novartis Business Services ernannt…
• Press Release May 16, 2018

  At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth

  Full pipeline of late stage assets with blockbuster potential Positioned to deliver sales growth and margin expansion through 2022 Pipeline depth in key therapeutic areas and building new,…
• Press Release May 16, 2018

  Novartis announces changes to the Executive Committee

  Felix R. Ehrat, Group General Counsel, will retire on June 1, 2018 Shannon Thyme Klinger appointed to Group General Counsel Robert Weltevreden appointed Head of Novartis Business Services…
• Press Release May 15, 2018

  Novartis successfully completes acquisition of AveXis, Inc.

  The digital press release with multimedia content can be accessed here:  Basel, May 15, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that it has completed the acquisition of…
• Press Release May 15, 2018

  Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)

  ARROW study to assess the mechanistic superiority of direct IL-17A inhibition (Cosentyx) over IL-23 inhibition (Tremfya®*) in clearing of Stelara®*-resistant psoriatic plaques[1] This is the…
• Press Release May 15, 2018

  Novartis completes tender offer for all outstanding shares of AveXis, Inc.

  Basel, May 15, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Novartis AM…
• Press Release May 12, 2018

  Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

  New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)[1]   In a…
• 
  Story May 07, 2018 Discovery

  Machine learning poised to accelerate drug discovery

  Technology used to tag friends on social media could change the way drug discovery is done.

• Press Release May 07, 2018

  Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally

  Alcon Cares to donate 100 reprocessed Infiniti® units to clinics helping underserved patients in Asia, Central and South America, and Africa over the next three years  Program to increase…
• Press Release May 03, 2018

  AveXis Reports First Quarter 2018 Financial and Operating Results

  -- Significant progress across operating functions including licensing, clinical trials  and regulatory interactions -- -- AVXS-101 pre-BLA meeting with FDA is scheduled to be…
• Key Release May 02, 2018

  Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab

  Holzkirchen, May 2, 2018 - Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing…